Safety and tolerability of olopatadine 0.2% in children and adolescents

Journal of Ocular Pharmacology and Therapeutics

Volumn 23, Issue 4, 2007, Pages 366-371

  Lichtenstein, Steven J ^a   Pasquine, Terry A ^b   Edwards, Michael R ^b   Wells, David T ^b   Gross, Robert D ^c   Robertson, Stella M ^b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b ALCON RESEARCH LTD   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLOPATADINE; PLACEBO; ANTIALLERGIC AGENT; DIBENZOXEPIN DERIVATIVE; EYE DROPS;

ADOLESCENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EYE DISCOMFORT; EYE EXAMINATION; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; MALE; RANDOMIZED CONTROLLED TRIAL; SLIT LAMP; VISUAL ACUITY; BLOOD PRESSURE; DRUG EFFECT; EYE FUNDUS; HEART RATE; PRESCHOOL CHILD;

ADOLESCENT; ANTI-ALLERGIC AGENTS; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; DIBENZOXEPINS; DOUBLE-BLIND METHOD; FEMALE; FUNDUS OCULI; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; VISUAL ACUITY;

EID: 35848943277     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0013     Document Type: Article

References (22)

1. Ciprandi, G., Buscaglia, S., Cerqueti, P.M., et al. Drug treatment of allergic conjunctivitis - a review of the evidence. Drugs 43:154-176, 1992.
2. 2-enriched atmospheres. Ann Allergy Asthma Immunol. 88(3):279-282, 2002.
3. Riediker, M., Monn, C., Koller, T., et al. Air pollutants enhance rhinoconjunctivitis symptoms in pollen allergic individuals. Ann. Allergy Asthma Immunol. 87: 311-318, 2001.
4. Behrendt, H., Becker, W.M., and Friedrichs, K.H. Interaction between aeroallergens and airborne particulate matter. Int. Arch. Allergy Immunol. 99:425-428, 1992.
5. Richter, A., Anton, S.E., Koch, P., et al. The impact of reducing dose frequency on health outcomes. Clin. Ther. 25:8:2307-2335, 2003.
6. Patel, S.C., and Spaeth, G.L. Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surg. 26:3:233-236,1995.
7. Walia, M., Lodha, R., Kabra, S.K. Montelukast in pediatric asthma management. Ind. J. Pediatr. 73(4):275-282, 2006.
8. Beck-Peccoz, P., Persani, L., and LaFranchi, S. Safety of medications and hormones used in the treatment of pediatric thyroid disorders. Pediatr. Endocrinol. Rev. 2(Suppl 1):124-133, 2004.
9. Abelson, M.B. A review of olopatadine for the treatment of ocular allergy. Exp. Opin. Pharmacother. 5(9): 1979-1994, 2004.
10. Rosenwasser, L.J., O'Brien, T., and Weyne, J. Mast cell stabilization and antihistamine effects of olopatadine ophthalmic solution: A review of preclinical and clinical research. Curr. Med. Res. Opin. 21(9):1377-1387, 2005.
11. Butrus, S., Greiner, J.V., Discepola, M., et al. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1 ophthalmic solution and nedocromil sodium 2 ophthalmic solution in the human conjunctival allergen challenge model. Clin. Ther. 22: 1462-1472, 2000.
12. Berdy, G.J., Stoppel, J.O., and Epstein, A.B. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1 ophthalmic solution and loteprednol etabonate 0.2 ophthalmic suspension in the conjunctival allergen challenge model. Clin. Ther. 24:918-929, 2002.
13. Aguilar, A.J. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1 olopatadine hydrochloride versus 0.05 ketotifen fumarate. Acta. Ophthalmol. Scand. Suppl. (230): 78:52-55, 2000.
14. Lanier, B.Q., Finegold, I., D'Arienzo, P., et al. Clinical efficacy of olopatadine versus epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr. Med. Res. Opin. 20(8):1227-1233, 2004.
15. Katelaris, C.H., Ciprandi, G., Missotten, L., et al. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1 ophthalmic solution and cromolyn sodium 2 ophthalmic solution in seasonal allergic conjunctivitis. Clin. Ther. 24(10):1561-1575, 2002.
16. Abelson, M.B., and Spitalny, L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am. J. Ophthalmol. 125:797-804, 1998.
17. Artal, M.N., Luna, J.D., and Discepola, M. A forced choice comfort of olopatadine versus ketotifen fumarate 0.05. Acta. Ophthalmol. Scand. Suppl. (230) 78:64-65, 2000.
18. Leonardi, A., and Zafirakis, P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: A double-masked environmental study of patient preference. Curr. Med. Res. Opin. 20:1167-1173, 2004.
19. Ciprandi, G., Turner, D., and Gross, R. Double-masked, randomized, parallel-group study comparing olopatadine 0.1 ophthalmic solution with cromolyn sodium 2 and levocabastine 0.05 ophthalmic preparations in children with seasonal allergic conjunctivitis. Curr. Ther. Res. Clin. Exp. 65:186-199, 2004.
20. Abelson, M.B., Greiner, J.V., Gomes, P., et al. Olopatadine reduces the ocular itching and redness of allergic conjunctivitis 24 hours after instillation. [abstract] Western Society of Allergy Asthma and Immunology (WSAAI). Hawaii, 2003.
21. Vogelson, C.T., Abelson, M.B., Pasquine, T., et al. Preclinical and clinical antiallergic effect of olopatadine 0.2 solution 24 hours after topical ocular administration. Allergy Asthma Proc. 25(1):69-75, 2004.
22. Abelson, M.B., Gomes, P.J., Vogelson, C.T., et al. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2 compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: A randomized, double-masked environmental study. Clin. Ther. 26(8):1237-1248, 2004.